DGAP-Adhoc: 4basebio AG: 4basebio AG decides to buy back 2 million treasury shares for further use in accordance with the authorizing resolution

/

4basebio AG decides to buy back 2 million treasury shares
for further use in accordance with the authorizing resolution

Heidelberg, Germany, and Cambridge, UK, 21 January 2020 - The management board of 4basebio AG (formerly Expedeon AG) (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) has decided today, based on the authorization of the general meeting of 19 December 2019 and with the approval of the supervisory board, to acquire up to 2,056,452 treasury shares (approx. 4% of the current share capital of the company) within the scope of a share buyback offer.

The acquisition shall take place within the framework of a voluntary public share buyback offer against payment of a cash consideration in a purchase price range of EUR 1.60 to EUR 1.85 per share (excluding incidental acquisition costs). The final purchase price per 4basebio share will be determined by the company after expiry of the acceptance period in accordance with the offer document. Shareholders may tender shares for buyback during the period from 27 January 2020, 0:00 a.m. to 10 February 2020, 12:00 p.m. (local time Frankfurt am Main). To the extent necessary and legally permissible, the buyback offer may be extended, suspended and also resumed by the company at any time. The company also reserves the right to increase the scope of the buyback offer.

The share buyback is aimed at a balanced use of the currently comparatively high level of freely available liquid funds, some of which are intended to benefit the shareholders. 4basebio AG is considering retaining the repurchased shares in treasury until further notice in order to use them later in accordance with the authorisation granted by the Annual General Meeting on 19 December 2019 - for example as consideration for the acquisition of companies or equity interests as part of its ongoing buy & build strategy. Shares not otherwise required will be redeemed.

Further details of the public buyback offer can be found in the offer document, which will be published on 24 January 2020, i.e. before the beginning of the acceptance period, on the company's website (www.investors.4basebio.com) under the heading "News" and in the German Federal Gazette (Bundesanzeiger).

*** end of ad hoc announcement ***

For further information, please contact:

4basebio AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: [email protected]
Investors' information: investors.4basebio.com

MC Services AG (Investor Relations and International Media Relations)
Julia Hofmann
Phone: +49 89 210228 0
Email: [email protected]

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###